Arcus Biosciences’ $138 Million Initial Public Offering

Ambrogio Visconti

Gunderson Dettmer advised Arcus Biosciences on the deal Arcus Biosciences (NYSE: RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the pricing…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

…

This content is for Standard 1 Year members only.
Login Join Now